Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for PerturbAI
- ·The full record, as it builds
Funding rounds
No funding rounds for PerturbAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PerturbAI
Developer of an AI (artificial intelligence)-native therapeutics platform intended to accelerate drug discovery and development through systems-level understanding of diseases. The company offers scalable in vivo CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) perturbation combined with AI-driven mapping of biological circuits, enabling pharmaceutical researchers and biotechnology organizations to develop therapeutics based on causal insights from intact organisms.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 5
- Website
- perturb.ai/
- Ownership
- Privately Held (backing)
PerturbAI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PerturbAI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PerturbAI in its N-PORT filings yet. We sweep new filings monthly.